Home
Conditions
Immunoproliferative Disorders

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,951 public trials 2,018 recruiting studies

Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Recruiting

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

NCT04972942

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations: Phoenix Children's Hospital Phoeniz, Arizona, United States

Loma Linda University Children's Hospital Loma Linda, California, United States

University of California Los Angeles, California, United States

University of California San Francisco, California, United States

View all 16 locations

View Trial Details

Recruiting

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

NCT06839456

Conditions: Acquired Aplastic Anemia, Anemia, Anemia, Refractory, +35 more
Locations: Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States

View Trial Details

Recruiting

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

NCT05336383

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Recruiting

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

NCT07107529

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: IT-Ascoli Piceno-Ospedale Mazzoni [01-016] Ascoli Piceno, Italy

IT-Bari-A.O.U. Consorziale Policlinico - Medicina Interna [01-018] Bari, Italy

IT-Bergamo-A.O. Papa Giovanni XXIII [01-003] Bergamo, Italy

IT-Bologna-A.O.U. di Bologna - Policlinico S. Orsola Malpighi [01-004] Bologna, Italy

View all 29 locations

View Trial Details

Recruiting

Establishment of a Phamacokinetik Model for Erwinase Pharmacokinetiks: The Aim of This Sub Study is to Optimize Target Trough Attainment While Minimizing High Exposures That Impose Increased Risk of Side Effects Such as Hyperammonemia

NCT07499349

Conditions: Acute Lymphoblastic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations: Aarhus University Hospital Aarhus, Denmark

View Trial Details

Recruiting

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

NCT04491370

Conditions: B-cell Lymphoma, Burkitt Lymphoma, DNA Virus Infections, +27 more
Locations: New York Medical Center Valhalla, New York, United States

View Trial Details

Recruiting

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

NCT07382739

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Elranatamab, +19 more
Locations: MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Recruiting

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

NCT02392572

Conditions: Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +18 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Recruiting

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

NCT05998642

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations: Arthur J.E. Child Comprehensive Cancer Centre Calgary, Alberta, Canada

BCCA - Vancouver Vancouver, British Columbia, Canada

Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada

Ottawa Hospital Research Institute Ottawa, Ontario, Canada

View Trial Details

Recruiting

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

NCT05996185

Conditions: Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +19 more
Locations: Yale Cancer Center, Clinical Trials Office New Haven, Connecticut, United States

Icahn School of Medicine at Mount Sinai New York, United States

View Trial Details

Immunoproliferative Disorders

Immunoproliferative Disorders trial results

Related conditions